Search International and National Patent Collections

1. (WO2017054141) HER2 LINEAR EPITOPE NEUTRALIZING ACTIVITY MONOCLONAL ANTIBODY AND USE THEREOF

Pub. No.:    WO/2017/054141    International Application No.:    PCT/CN2015/091127
Publication Date: Fri Apr 07 01:59:59 CEST 2017 International Filing Date: Wed Sep 30 01:59:59 CEST 2015
IPC: C07K 16/30
C12N 5/18
C12N 15/13
C12N 15/06
A61K 39/395
A61P 35/00
Applicants: ABMAX BIOTECHNOLOGY CO., LTD.
北京天成新脉生物技术有限公司
Inventors: SUN, Le
孙乐
LI, Maohua
李茂华
ZHANG, Cuijuan
张翠娟
ZHANG, Xiaogang
张小刚
WANG, Muyang
王慕旸
Title: HER2 LINEAR EPITOPE NEUTRALIZING ACTIVITY MONOCLONAL ANTIBODY AND USE THEREOF
Abstract:
Provided are an HER2 linear epitope neutralizing activity monoclonal antibody and a preparation method thereof. The method comprises coupling a polypeptide containing amino acids at positions 374-398 of the HER2 and a carrier protein, and immunizing mice to prepare the monoclonal antibody secreting a plurality of hybridoma cells, same being capable of specifically recognizing the HER2 of the cell surface of breast cancer, and having a neutralizing activity. The polypeptide can be used to prepare the HER2 monoclonal antibody and therapeutic drugs for treating diseases targeted at HER2; and the binding affinity of the monoclonal antibody and the HER2 is between 1-4nM, and can be used in combination with Trastuzumab or Pertuzumab.